-+ 0.00%
-+ 0.00%
-+ 0.00%
Opus Genetics Says Global RDH12 Alliance Commits Up To $1.6M To Advance OPGx-RDH12 Development For RDH12-LCA Treatment
Share
Listen to the news

The clinical program is being advanced through a strategic collaboration with the Global RDH12 Alliance, which brings together RDH12 Fund for Sight in the United States and Eyes on the Future in the United Kingdom. Established in July 2025, the collaboration combines patient advocacy, scientific expertise and development resources with the goal of accelerating progress toward a potential treatment for RDH12-LCA. Under the agreement, the Alliance committed up to $1.6 million toward the development of OPGx-RDH12, with eligible development costs reimbursed as activities are completed, subject to certain diligence obligations and milestones.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending